一种新型的迟发型超敏反应在 SARS-CoV-2 暴露个体中测量细胞免疫反应的应用。
A novel application of delayed-type hipersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals.
机构信息
Immunology Lab, Central Lab, Floor - 1, Main Building, Hospital Universitario de Canarias, Ctra Ofra s/n. La Cuesta, 38320 La Laguna, Tenerife, Spain.
Allergy Service, Floor-2, Outpatient Building, Hospital Universitario de Canarias, Ctra Ofra s/n. La Cuesta, 38320 La Laguna, Tenerife, Spain.
出版信息
Clin Immunol. 2021 May;226:108730. doi: 10.1016/j.clim.2021.108730. Epub 2021 Apr 16.
OBJECTIVE
To understand the anti-virus adaptive immune response occurring during SARS-Cov-2 infection is necessary to have methods to investigate cellular and humoral components. The goal of this study has been to investigate the utility of a specific spike-DTH test using a coronavirus recombinant protein in COVID-19 patients.
METHODS
DTH studies were performed by intradermal injection of a commercial recombinant spike protein from SARS-CoV-2 along with conventional serology studies.
RESULTS
Fifty-one COVID-19 patients were studied showing 84,3% of concordance with spike-DTH and anti-RBD-IgG. Spike-DTH was superior to identify seven more COVID-19 individuals. A high specificity was found with no positive spike DTH reactions in the non-sick individuals. The skin test also showed more stable results over time while specific anti-RBD-IgG decreased gradually. Clinical severity groups also showed a progressive gradient of larger positive spike-DTH.
CONCLUSION
Specific spike DTH test seems to be an easy method to study cell immune response.
目的
了解 SARS-CoV-2 感染过程中发生的抗病毒适应性免疫反应，有必要研究细胞和体液成分的方法。本研究的目的是调查使用冠状病毒重组蛋白在 COVID-19 患者中进行特异性刺突 DTH 测试的效用。
方法
通过皮内注射 SARS-CoV-2 的商业重组刺突蛋白进行 DTH 研究，并结合常规血清学研究。
结果
研究了 51 例 COVID-19 患者，显示出与刺突-DTH 和抗 RBD-IgG 的 84.3%的一致性。刺突-DTH 更能识别出另外 7 例 COVID-19 患者。在非患病个体中未发现阳性刺突 DTH 反应，特异性高。皮肤试验也显示出随着时间的推移更稳定的结果，而特异性抗 RBD-IgG 逐渐减少。临床严重程度组也显示出更大的阳性刺突-DTH 逐渐增加的梯度。
结论
特异性刺突 DTH 测试似乎是研究细胞免疫反应的一种简单方法。
Zotero 插件